Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 539-547

  Tesse, Angela ^a,b,c   Al Massarani, Ghassan ^b   Wangensteen, Rosemary ^b   Reitenbach, Sebastien ^b   Martínez, M Carmen ^a,b,c   Andriantsitohaina, Ramaroson ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CHOLESTEROL; CYCLOOXYGENASE 2; DACTINOMYCIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR INFLAMMATION; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ELECTRON SPIN RESONANCE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; T LYMPHOCYTE; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 38749117138     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.130278     Document Type: Article

References (40)

1. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, and Freyssinet JM (1997) The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 99:1546-1554.
2. Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, and Tremblay A (2006) A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor γ-dependent pathway. Mol Endocrinol 20:3165-3178.
3. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, and Ahn YS (2003) High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 145:962-970.
4. Boden G and Zhang M (2006) Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 15:243-250.
5. Chen F, Wang M, O'Connor JP, He M, Tripathi T, and Harrison LE (2003) Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-κβ. J Cell Biochem 90:732-744.
6. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, and Kim TS (2000) Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB. J Biol Chem 275:32681-32687.
7. Colville-Nash PR, Qureshi SS, Willis D, and Willoughby DA (1998) Inhibition of inducible nitric oxide synthase by peroxisome proliferator- activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol 161:978-984.
8. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, et al. (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur J Pharmacol 483:79-93.
9. Escher P and Wahli W (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448:121-138.
10. Esposito K, Ciotola M, and Giugliano D (2006) Pioglitazone reduces endothelial microparticles in the metabolic syndrome. Arterioscler Thromb Vasc Biol 26:1926-1927.
11. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, and Glass CK (1999) Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-382.
12. Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM, and Scrobohaci ML (1999) Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 93:3451-3456.
13. Inoue H, Tanabe T, and Umesono K (2000) Feedback control of cyclooxygenase-2 expression through PPARγ. J Biol Chem 275:28028-28032.
14. Jiang C, Ting AT, and Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86.
15. Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, and Evans LM (2007) Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus: an effect probably mediated by direct platelet PPARγ activation. Atherosclerosis, in press.
16. Knedler A and Ham RG (1987) Optimized medium for clonal growth of human microvascular endothelial cells with minimal serum. In Vitro Cell Dev Biol 23:481-491.
17. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, and Glass CK (2000) Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531.
18. Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, and Corbett JA (2000) Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49:346-355.
19. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, and Tedgui A (2000) Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101:841-843.
20. Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, Sasso FC, Portoghese M, Cirillo F, Cacciapuoti F, et al. (2006) The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55:622-632.
21. Martin S, Tesse A, Hugel B, Martínez MC, Morel O, Freyssinet JM, and Andriantsitohaina R (2004) Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 109:1653-1659.
22. Martínez MC, Tesse A, Zobairi F, and Andriantsitohaina R (2005) Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 288:H1004- H1009.
23. Mesri M and Altieri DC (1998) Endothelial cell activation by leukocyte microparticles. J Immunol 161:4382-4387.
24. Mesri M and Altieri DC (1999) Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 274:23111-23118.
25. Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, Schneider F, and Andriantsitohaina R (2006) Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol 169:1473-1483.
26. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, and Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820.
27. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, and Dandona P (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728-2735.
28. Mülsch A, Mordvintcev P, Bassenge E, Jung F, Clement B, and Busse R (1995) In vivo spin trapping of glyceryl trinitrate-derived nitric oxide in rabbit blood vessels and organs. Circulation 92:1876-1882.
29. Murao K, Imachi H, Momoi A, Sayo Y, Hosokawa H, Sato M, Ishida T, and Takahara J (1999) Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 454:27-30.
30. Ohlmann P, Tesse A, Loichot C, Ralay Ranaivo H, Roul G, Philippe C, Watterson DM, Haiech J, and Andriantsitohaina R (2005) Deletion of MLCK210 induces subtle changes in vascular reactivity but does not affect cardiac function. Am J Physiol Heart Circ Physiol 289:H2342-H2349.
31. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, and Glass CK (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763.
32. Ralay Ranaivo H, Rakotoarison O, Tesse A, Schott C, Randriantsoa A, Lobstein A, and Andriantsitohaina R (2004) Cedrelopsis grevei induced hypotension and improved endothelial vasodilatation through an increase of Cu/Zn SOD protein expression. Am J Physiol Heart Circ Physiol 286:H775-H781.
33. Ryan MJ, Didion SP, Mathur S, Faraci FM, and Sigmund CD (2004) PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43:661-666.
34. Sabatier F, Darmon P, Hugel B, Combes V, Sammarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, et al. (2002) Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 51:2840-2845.
35. Sauma L, Stenkula KG, Kjølhede P, Strålfors P, Söderström M, and Nystrom FH (2006) PPAR-γ response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 22:60-68.
36. Semple RK, Chatterjee VK, and O'Rahilly S (2006) PPARγ and human metabolic disease. J Clin Invest 116:581-589.
37. Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RM, and Ahn YS (2005) Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 33:2540-2546.
38. Tesse A, Martinez MC, Hugel B, Chalupsky K, Muller CD, Meziani F, Mitolo-Chieppa D, Freyssinet JM, and Andriantsitohaina R (2005) Upregulation of proinflammatory proteins through NF-κB pathway by shed membrane microparticles results in vascular hyporeactivity. Arterioscler Thromb Vasc Biol 25:2522-2527.
39. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, and Whittaker P (2003) PPAR-α and -γ but not -δ- agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-κB-independent effect. Br J Pharmacol 139:163-171.
40. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepa A, and Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3:research0034.1-research0034.11.